PSI™ Enables Cell Engineering and Therapy from Discovery to Predicting Outcome

Learn how PSI can help you discover and reveal the key potent cell subsets that correlate to in vivo outcome in cell therapy throughout discovery and development.

Your data is in safe hands: we'll never sell it to third parties and you may always unsubscribe. Privacy Policy.

Ensuring the continued success of engineered immune cell therapies in the fight against cancer

CAR-T cell-based immunotherapies have had remarkable success in recent years. CAR T-cell therapy was shown to lead to a 67%- 90% complete remission (CR) rate in adults and children with relapsed/refractory acute lymphoblastic leukemia (R/R ALL) [4-8] while only 29% of adult R/R ALL patients achieved CR with chemotherapy.

In this Application Note we:
  • Use Polyfunctionality and PSI to reveal synergies and mechanism with novel Combination Therapies
  • Use PSI to clearly reveal differences in bioprocessing methods for product manufacturing process optimization
  • Predict patient response to a CAR-T therapy using pre-infusion product PSI, demonstrating its potential as a biomarker for clinical outcome